evenamide

Evenamide is an orally available, small molecule drug developed by Newron Pharmaceuticals as a selective voltage-gated sodium channel blocker, targeting subtypes including Nav1.3, Nav1.7, and Nav1.8[1][4][8]. Its primary mechanism is the inhibition of excessive glutamate release associated with NMDA receptor hypofunction, without affecting basal glutamate levels[2][5]. Evenamide acts as a modulator of sustained repetitive neuronal firing and normalizes aberrant synaptic glutamate transmission implicated in schizophrenia and other neuropsychiatric disorders[6][8]. It does not interact with monoaminergic pathways or over 130 other CNS targets except sodium channels[6][8]. The drug is being developed primarily as an adjunctive therapy for treatment-resistant schizophrenia (TRS), showing efficacy in both preclinical models (psychosis, mania, depression) and clinical trials as an add-on to antipsychotics such as risperidone or aripiprazole[2][5][7]. Clinical studies have demonstrated significant improvements in symptoms for patients with TRS who are inadequately responsive to current antipsychotic medications; it has reached Phase III development for schizophrenia and Phase II/III for broader psychiatric disorders[4].

Other names

evenamideNW-3509NW3509NW 3509NW-3509ANW3509ANW 3509A